A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT ID: NCT01492361

Last Updated: 2022-04-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

8179 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AMR101 (icosapent ethyl \[ethyl-EPA\]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMR101

AMR101 (icosapent ethyl) + statin therapy, daily

Group Type EXPERIMENTAL

AMR101

Intervention Type DRUG

Parallel Assignment

Statin therapy

Intervention Type DRUG

Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)

Placebo

Placebo + statin therapy, daily

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Parallel Assignment

Statin therapy

Intervention Type DRUG

Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMR101

Parallel Assignment

Intervention Type DRUG

Placebo

Parallel Assignment

Intervention Type DRUG

Statin therapy

Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VASCEPA® (icosapent ethyl) matching placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and non-pregnant or sterile women ages 45 and older
* Hypertriglyceridemia
* On statin therapy for at least four weeks
* Either having established cardiovascular disease or at high risk for cardiovascular disease

Exclusion Criteria

* Severe heart failure
* Any life-threatening disease other than cardiovascular disease
* Active severe liver disease
* Hemoglobin A1c \>10.0%
* Poorly controlled hypertension
* Planned coronary intervention (such as stent placement or heart bypass) or any non-cardiac major surgical procedure
* Known familial lipoprotein lipase deficiency (Fredrickson Type I), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III)
* Known hypersensitivity to the study product, fish and/or shellfish, or placebo
* History of acute or chronic pancreatitis
* Patients are excluded if using the following medications:

* PCSK9 inhibitors
* niacin \>200 mg/day or fibrates;
* any omega-3 fatty acid medications ;
* dietary supplements containing omega-3 fatty acids (e.g., flaxseed oil, fish oil, krill oil, or algal oil);
* bile acid sequestrants
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amarin Pharma Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deepak L. Bhatt, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital, 75 Francis Street, Boston

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Amarin Investigational Site

Birmingham, Alabama, United States

Site Status

Amarin Investigational Site

Birmingham, Alabama, United States

Site Status

Amarin Investigational Site

Huntsville, Alabama, United States

Site Status

Amarin Investigational Site

Mobile, Alabama, United States

Site Status

Amarin Investigational Site

Muscle Shoals, Alabama, United States

Site Status

Amarin Investigational Site

Mesa, Arizona, United States

Site Status

Amarin Investigational Site

Phoenix, Arizona, United States

Site Status

Amarin Investigational Site

Tucson, Arizona, United States

Site Status

Amarin Investigational Site

Little Rock, Arkansas, United States

Site Status

Amarin Investigational Site

Beverly Hills, California, United States

Site Status

Amarin Investigational Site

Chino, California, United States

Site Status

Amarin Investigational Site

Concord, California, United States

Site Status

Amarin Investigational Site

El Cajon, California, United States

Site Status

Amarin Investigational Site

Encino, California, United States

Site Status

Amarin Investigational Site

Fair Oaks, California, United States

Site Status

Amarin Investigational Site

Hawaiian Gardens, California, United States

Site Status

Amarin Investigational Site

Lancaster, California, United States

Site Status

Amarin Investigational Site

Lincoln, California, United States

Site Status

Amarin Investigational Site

Los Angeles, California, United States

Site Status

Amarin Investigational Site

Los Angeles, California, United States

Site Status

Amarin Investigational Site

Los Angeles, California, United States

Site Status

Amarin Investigational Site

National City, California, United States

Site Status

Amarin Investigational Site

Orange, California, United States

Site Status

Amarin Investigational Site

Paramount, California, United States

Site Status

Amarin Investigational Site

Roseville, California, United States

Site Status

Amarin Investigational Site

San Diego, California, United States

Site Status

Amarin Investigational Site

Torrance, California, United States

Site Status

Amarin Investigational Site

Ventura, California, United States

Site Status

Amarin Investigational Site

Walnut Creek, California, United States

Site Status

Amarin Investigational Site

Aurora, Colorado, United States

Site Status

Amarin Investigational Site

Colorado Springs, Colorado, United States

Site Status

Amarin Investigational Site

Golden, Colorado, United States

Site Status

Amarin Investigational Site

Guilford, Connecticut, United States

Site Status

Amarin Investigational Site

Hartford, Connecticut, United States

Site Status

Amarin Investigational Site

Newark, Delaware, United States

Site Status

Amarin Investigational Site

Wilmington, Delaware, United States

Site Status

Amarin Investigational Site

Washington D.C., District of Columbia, United States

Site Status

Amarin Investigational Site

Boynton Beach, Florida, United States

Site Status

Amarin Investigational Site

Bradenton, Florida, United States

Site Status

Amarin Investigational Site

Clearwater, Florida, United States

Site Status

Amarin Investigational Site

Edgewater, Florida, United States

Site Status

Amarin Investigational Site

Fleming Island, Florida, United States

Site Status

Amarin Investigational Site

Fort Lauderdale, Florida, United States

Site Status

Amarin Investigational Site

Fort Lauderdale, Florida, United States

Site Status

Amarin Investigational Site

Inverness, Florida, United States

Site Status

Amarin Investigational Site

Jacksonville, Florida, United States

Site Status

Amarin Investigational Site

Jacksonville, Florida, United States

Site Status

Amarin Investigational Site

Jacksonville, Florida, United States

Site Status

Amarin Investigational Site

Jacksonville, Florida, United States

Site Status

Amarin Investigational Site

Miami, Florida, United States

Site Status

Amarin Investigational Site

Miami, Florida, United States

Site Status

Amarin Investigational Site

Miami Beach, Florida, United States

Site Status

Amarin Investigational Site

Miami Lakes, Florida, United States

Site Status

Amarin Investigational Site

Ocala, Florida, United States

Site Status

Amarin Investigational Site

Orlando, Florida, United States

Site Status

Amarin Investigational Site

Pembroke Pines, Florida, United States

Site Status

Amarin Investigational Site

Plantation, Florida, United States

Site Status

Amarin Investigational Site

Safety Harbor, Florida, United States

Site Status

Amarin Investigational Site

Sarasota, Florida, United States

Site Status

Amarin Investigational Site

St. Petersburg, Florida, United States

Site Status

Amarin Investigational Site

Vero Beach, Florida, United States

Site Status

Amarin Investigational Site

West Palm Beach, Florida, United States

Site Status

Amarin Investigational Site

Conyers, Georgia, United States

Site Status

Amarin Investigational Site

Covington, Georgia, United States

Site Status

Amarin Investigational Site

Cumming, Georgia, United States

Site Status

Amarin Investigational Site

Roswell, Georgia, United States

Site Status

Amarin Investigational Site

Honolulu, Hawaii, United States

Site Status

Amarin Investigational Site

Addison, Illinois, United States

Site Status

Amarin Investigational Site

Chicago, Illinois, United States

Site Status

Amarin Investigational Site

Norman, Illinois, United States

Site Status

Amarin Investigational Site

North Chicago, Illinois, United States

Site Status

Amarin Investigational Site

Peoria, Illinois, United States

Site Status

Amarin Investigational Site

Winfield, Illinois, United States

Site Status

Amarin Investigational Site

Evansville, Indiana, United States

Site Status

Amarin Investigational Site

Iowa City, Iowa, United States

Site Status

Amarin Investigational Site

Wichita, Kansas, United States

Site Status

Amarin Investigational Site

Wichita, Kansas, United States

Site Status

Amarin Investigational Site

Louisville, Kentucky, United States

Site Status

Amarin Investigational Site

Alexandria, Louisiana, United States

Site Status

Amarin Investigational Site

Eunice, Louisiana, United States

Site Status

Amarin Investigational Site

Marrero, Louisiana, United States

Site Status

Amarin Investigational Site

Auburn, Maine, United States

Site Status

Amarin Investigational Site

Baltimore, Maryland, United States

Site Status

Amarin Investigational Site

Lutherville, Maryland, United States

Site Status

Amarin Investigational Site

Takoma Park, Maryland, United States

Site Status

Amarin Investigational Site

Boston, Massachusetts, United States

Site Status

Amarin Investigational Site

Boston, Massachusetts, United States

Site Status

Amarin Investigational Site

Fall River, Massachusetts, United States

Site Status

Amarin Investigational Site

Lansing, Michigan, United States

Site Status

Amarin Investigational Site

Marquette, Michigan, United States

Site Status

Amarin Investigational Site

Troy, Michigan, United States

Site Status

Amarin Investigational Site

Saint Cloud, Minnesota, United States

Site Status

Amarin Investigational Site

Biloxi, Mississippi, United States

Site Status

Amarin Investigational Site

Tupelo, Mississippi, United States

Site Status

Amarin Investigational Site

Chesterfield, Missouri, United States

Site Status

Amarin Investigational Site

City of Saint Peters, Missouri, United States

Site Status

Amarin Investigational Site

Florissant, Missouri, United States

Site Status

Amarin Investigational Site

Jefferson City, Missouri, United States

Site Status

Amarin Investigational Site

Kansas City, Missouri, United States

Site Status

Amarin Investigational Site

St Louis, Missouri, United States

Site Status

Amarin Investigational Site

Hastings, Nebraska, United States

Site Status

Amarin Investigational Site

Omaha, Nebraska, United States

Site Status

Amarin Investigational Site

Omaha, Nebraska, United States

Site Status

Amarin Investigational Site

Henderson, Nevada, United States

Site Status

Amarin Investigational Site

Las Vegas, Nevada, United States

Site Status

Amarin Investigational Site

Ocean City, New Jersey, United States

Site Status

Amarin Investigational Site

Albuquerque, New Mexico, United States

Site Status

Amarin Investigational Site

Albany, New York, United States

Site Status

Amarin Investigational Site

Brooklyn, New York, United States

Site Status

Amarin Investigational Site

Great Neck, New York, United States

Site Status

Amarin Investigational Site

Liverpool, New York, United States

Site Status

Amarin Investigational Site

New York, New York, United States

Site Status

Amarin Investigational Site

New York, New York, United States

Site Status

Amarin Investigational Site

North Massapequa, New York, United States

Site Status

Amarin Investigational Site

Smithtown, New York, United States

Site Status

Amarin Investigational Site

Vestal, New York, United States

Site Status

Amarin Investigational Site

West Seneca, New York, United States

Site Status

Amarin Investigational Site

Charlotte, North Carolina, United States

Site Status

Amarin Investigational Site

Durham, North Carolina, United States

Site Status

Amarin Investigational Site

Gastonia, North Carolina, United States

Site Status

Amarin Investigational Site

Kernersville, North Carolina, United States

Site Status

Amarin Investigational Site

Raleigh, North Carolina, United States

Site Status

Amarin Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Amarin Investigational Site

Fargo, North Dakota, United States

Site Status

Amarin Investigational Site

Cincinnati, Ohio, United States

Site Status

Amarin Investigational Site

Dayton, Ohio, United States

Site Status

Amarin Investigational Site

Lorain, Ohio, United States

Site Status

Amarin Investigational Site

Sandusky, Ohio, United States

Site Status

Amarin Investigational Site

Tulsa, Oklahoma, United States

Site Status

Amarin Investigational Site

Bend, Oregon, United States

Site Status

Amarin Investigational Site

Portland, Oregon, United States

Site Status

Amarin Investigational Site

Beaver, Pennsylvania, United States

Site Status

Amarin Investigational Site

Doylestown, Pennsylvania, United States

Site Status

Amarin Investigational Site

Jersey Shore, Pennsylvania, United States

Site Status

Amarin Investigational Site

Newport, Pennsylvania, United States

Site Status

Amarin Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Amarin Investigational Site

Phoenixville, Pennsylvania, United States

Site Status

Amarin Investigational Site

Sellersville, Pennsylvania, United States

Site Status

Amarin Investigational Site

Tipton, Pennsylvania, United States

Site Status

Amarin Investigational Site

Wyomissing, Pennsylvania, United States

Site Status

Amarin Investigational Site

Yardley, Pennsylvania, United States

Site Status

Amarin Investigational Site

Lancaster, South Carolina, United States

Site Status

Amarin Investigational Site

Simpsonville, South Carolina, United States

Site Status

Amarin Investigational Site

Rapid City, South Dakota, United States

Site Status

Amarin Investigational Site

Bristol, Tennessee, United States

Site Status

Amarin Investigational Site

Columbia, Tennessee, United States

Site Status

Amarin Investigational Site

Germantown, Tennessee, United States

Site Status

Amarin Investigational Site

Jackson, Tennessee, United States

Site Status

Amarin Investigational Site

Knoxville, Tennessee, United States

Site Status

Amarin Investigational Site

Smyrna, Tennessee, United States

Site Status

Amarin Investigational Site

Austin, Texas, United States

Site Status

Amarin Investigational Site

Beaumont, Texas, United States

Site Status

Amarin Investigational Site

Carrollton, Texas, United States

Site Status

Amarin Investigational Site

Dallas, Texas, United States

Site Status

Amarin Investigational Site

Houston, Texas, United States

Site Status

Amarin Investigational Site

Houston, Texas, United States

Site Status

Amarin Investigational Site

Houston, Texas, United States

Site Status

Amarin Investigational Site

Houston, Texas, United States

Site Status

Amarin Investigational Site

Houston, Texas, United States

Site Status

Amarin Investigational Site

Houston, Texas, United States

Site Status

Amarin Investigational Site

Houston, Texas, United States

Site Status

Amarin Investigational Site

Hurst, Texas, United States

Site Status

Amarin Investigational Site

New Braunfels, Texas, United States

Site Status

Amarin Investigational Site

Plano, Texas, United States

Site Status

Amarin Investigational Site

San Antonio, Texas, United States

Site Status

Amarin Investigational Site

San Antonio, Texas, United States

Site Status

Amarin Investigational Site

Splendora, Texas, United States

Site Status

Amarin Investigational Site

Tomball, Texas, United States

Site Status

Amarin Investigational Site

West Jordan, Utah, United States

Site Status

Amarin Investigational Site

Falls Church, Virginia, United States

Site Status

Amarin Investigational Site

Manassas, Virginia, United States

Site Status

Amarin Investigational Site

Midlothian, Virginia, United States

Site Status

Amarin Investigational Site

Newport News, Virginia, United States

Site Status

Amarin Investigational Site

Burien, Washington, United States

Site Status

Amarin Investigational Site

Tacoma, Washington, United States

Site Status

Amarin Investigational Site

Huntington, West Virginia, United States

Site Status

Amarin Investigational Site

Camperdown, New South Wales, Australia

Site Status

Amarin Investigational Site

Lismore, New South Wales, Australia

Site Status

Amarin Investigational Site

Brisbane, Queensland, Australia

Site Status

Amarin Investigational Site

Chermside, Queensland, Australia

Site Status

Amarin Investigational Site

Bedford Park, South Australia, Australia

Site Status

Amarin Investigational Site

Launceston, Tasmania, Australia

Site Status

Amarin Investigational Site

Fitzroy, Victoria, Australia

Site Status

Amarin Investigational Site

Geelong, Victoria, Australia

Site Status

Amarin Investigational Site

Heidelberg Heights, Victoria, Australia

Site Status

Amarin Investigational Site

Melbourne, Victoria, Australia

Site Status

Amarin Investigational Site

Fremantle, Western Australia, Australia

Site Status

Amarin Investigational Site

Joondalup, Western Australia, Australia

Site Status

Amarin Investigational Site

Murdoch, Western Australia, Australia

Site Status

Amarin Investigational Site

Nedlands, Western Australia, Australia

Site Status

Amarin Investigational Site

Perth, Western Australia, Australia

Site Status

Amarin Investigational Site

Edmonton, Alberta, Canada

Site Status

Amarin Investigational Site

Coquitlam, British Columbia, Canada

Site Status

Amarin Investigational Site

Vancouver, British Columbia, Canada

Site Status

Amarin Investigational Site

Vancouver, British Columbia, Canada

Site Status

Amarin Investigational Site

Brampton, Ontario, Canada

Site Status

Amarin Investigational Site

Collingwood, Ontario, Canada

Site Status

Amarin Investigational Site

Corunna, Ontario, Canada

Site Status

Amarin Investigational Site

Newmarket, Ontario, Canada

Site Status

Amarin Investigational Site

Sarnia, Ontario, Canada

Site Status

Amarin Investigational Site

Strathroy, Ontario, Canada

Site Status

Amarin Investigational Site

Laval, Quebec, Canada

Site Status

Amarin Investigational Site

Montreal, Quebec, Canada

Site Status

Amarin Investigational Site

Montreal, Quebec, Canada

Site Status

Amarin Investigational Site

Saint-Charles-Borromée, Quebec, Canada

Site Status

Amarin Investigational Site

Sherbrooke, Quebec, Canada

Site Status

Amarin Investigational Site

Québec, , Canada

Site Status

Amarin Investigational Site

Québec, , Canada

Site Status

Amarin Investigational Site

Hyderabad, Andhra Pradesh, India

Site Status

Amarin Investigational Site

Hyderabad, Andhra Pradesh, India

Site Status

Amarin Investigational Site

Secunderabad, Andhra Pradesh, India

Site Status

Amarin Investigational Site

Visakhapatnam, Andhra Pradesh, India

Site Status

Amarin Investigational Site

Bangalore, Karnataka, India

Site Status

Amarin Investigational Site

Bangalore, Karnataka, India

Site Status

Amarin Investigational Site

Bangalore, Karnataka, India

Site Status

Amarin Investigational Site

Mysore, Karnataka, India

Site Status

Amarin Investigational Site

Mysore, Karnataka, India

Site Status

Amarin Investigational Site

Kottayam, Kerala, India

Site Status

Amarin Investigational Site

Mumbai, Maharashtra, India

Site Status

Amarin Investigational Site

Nashik, Maharashtra, India

Site Status

Amarin Investigational Site

Pune, Maharashtra, India

Site Status

Amarin Investigational Site

New Delhi, National Capital Territory of Delhi, India

Site Status

Amarin Investigational Site

New Delhi, National Capital Territory of Delhi, India

Site Status

Amarin Investigational Site

Chennai, Tamil Nadu, India

Site Status

Amarin Investigational Site

Coimbatore, Tamil Nadu, India

Site Status

Amarin Investigational Site

Almelo, , Netherlands

Site Status

Amarin Investigational Site

Amersfoort, , Netherlands

Site Status

Amarin Investigational Site

Blaricum, , Netherlands

Site Status

Amarin Investigational Site

Capelle aan den IJssel, , Netherlands

Site Status

Amarin Investigational Site

Den Helder, , Netherlands

Site Status

Amarin Investigational Site

Deventer, , Netherlands

Site Status

Amarin Investigational Site

Ede, , Netherlands

Site Status

Amarin Investigational Site

Eindhoven, , Netherlands

Site Status

Amarin Investigational Site

Enschede, , Netherlands

Site Status

Amarin Investigational Site

Goes, , Netherlands

Site Status

Amarin Investigational Site

Gorinchem, , Netherlands

Site Status

Amarin Investigational Site

Gouda, , Netherlands

Site Status

Amarin Investigational Site

Groningen, , Netherlands

Site Status

Amarin Investigational Site

Haarlem, , Netherlands

Site Status

Amarin Investigational Site

Harderwijk, , Netherlands

Site Status

Amarin Investigational Site

Heerenveen, , Netherlands

Site Status

Amarin Investigational Site

Heerlen, , Netherlands

Site Status

Amarin Investigational Site

Hoofddorp, , Netherlands

Site Status

Amarin Investigational Site

Leeuwarden, , Netherlands

Site Status

Amarin Investigational Site

Leiderdorp, , Netherlands

Site Status

Amarin Investigational Site

Nijmegen, , Netherlands

Site Status

Amarin Investigational Site

Roosendaal, , Netherlands

Site Status

Amarin Investigational Site

Rotterdam, , Netherlands

Site Status

Amarin Investigational Site

Rotterdam, , Netherlands

Site Status

Amarin Investigational Site

Rotterdam, , Netherlands

Site Status

Amarin Investigational Site

s'Hertogenbosch, , Netherlands

Site Status

Amarin Investigational Site

Schiedam, , Netherlands

Site Status

Amarin Investigational Site

Sneek, , Netherlands

Site Status

Amarin Investigational Site

The Hague, , Netherlands

Site Status

Amarin Investigational Site

Tilburg, , Netherlands

Site Status

Amarin Investigational Site

Tilburg, , Netherlands

Site Status

Amarin Investigational Site

Uden, , Netherlands

Site Status

Amarin Investigational Site

Veldhoven, , Netherlands

Site Status

Amarin Investigational Site

Zoetermeer, , Netherlands

Site Status

Amarin Investigational Site

Zutphen, , Netherlands

Site Status

Amarin Investigational Site

Takapuna, Auckland, New Zealand

Site Status

Amarin Investigational Site

Christchurch, , New Zealand

Site Status

Amarin Investigational Site

Dunedin, , New Zealand

Site Status

Amarin Investigational Site

Hamilton, , New Zealand

Site Status

Amarin Investigational Site

Hastings, , New Zealand

Site Status

Amarin Investigational Site

Nelson, , New Zealand

Site Status

Amarin Investigational Site

New Plymouth, , New Zealand

Site Status

Amarin Investigational Site

Takapuna Auckland, , New Zealand

Site Status

Amarin Investigational Site

Tauranga, , New Zealand

Site Status

Amarin Investigational Site

Whangarei, , New Zealand

Site Status

Amarin Investigational Site

Bialystok, , Poland

Site Status

Amarin Investigational Site

Bialystok, , Poland

Site Status

Amarin Investigational Site

Katowice, , Poland

Site Status

Amarin Investigational Site

Katowice, , Poland

Site Status

Amarin Investigational Site

Krakow, , Poland

Site Status

Amarin Investigational Site

Mikolów, , Poland

Site Status

Amarin Investigational Site

Skierniewice, , Poland

Site Status

Amarin Investigational Site

Tarnów, , Poland

Site Status

Amarin Investigational Site

Warsaw, , Poland

Site Status

Amarin Investigational Site

Warsaw, , Poland

Site Status

Amarin Investigational Site

Warszawska, , Poland

Site Status

Amarin Investigational Site

Wroclaw, , Poland

Site Status

Amarin Investigational Site

Wroclaw, , Poland

Site Status

Amarin Investigational Site

Zgierz, , Poland

Site Status

Amarin Investigational Site

Argeş, , Romania

Site Status

Amarin Investigational Site

Brăila, , Romania

Site Status

Amarin Investigational Site

Bucharest, , Romania

Site Status

Amarin Investigational Site

Bucharest, , Romania

Site Status

Amarin Investigational Site

Bucharest, , Romania

Site Status

Amarin Investigational Site

Bucharest, , Romania

Site Status

Amarin Investigational Site

Bucharest, , Romania

Site Status

Amarin Investigational Site

Bucharest, , Romania

Site Status

Amarin Investigational Site

Cluj-Napoca, , Romania

Site Status

Amarin Investigational Site

Constanța, , Romania

Site Status

Amarin Investigational Site

Craiova, Dolj, , Romania

Site Status

Amarin Investigational Site

Iași, , Romania

Site Status

Amarin Investigational Site

Maramureş, , Romania

Site Status

Amarin Investigational Site

Mureş, , Romania

Site Status

Amarin Investigational Site

Sibiu, , Romania

Site Status

Amarin Investigational Site

Târgu Mureş, , Romania

Site Status

Amarin Investigational Site

Timișoara, , Romania

Site Status

Amarin Investigational Site

Arkhangelsk, , Russia

Site Status

Amarin Investigational Site

Arkhangelsk, , Russia

Site Status

Amarin Investigational Site

Arkhangelsk, , Russia

Site Status

Amarin Investigational Site

Kazan', , Russia

Site Status

Amarin Investigational Site

Kazan', , Russia

Site Status

Amarin Investigational Site

Kemerovo, , Russia

Site Status

Amarin Investigational Site

Kemerovo, , Russia

Site Status

Amarin Investigational Site

Kirovsk, Leningradskaya Region, , Russia

Site Status

Amarin Investigational Site

Krasnodar, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Moscow, , Russia

Site Status

Amarin Investigational Site

Nizhny Novgorod, , Russia

Site Status

Amarin Investigational Site

Novosibirsk, , Russia

Site Status

Amarin Investigational Site

Novosibirsk, , Russia

Site Status

Amarin Investigational Site

Novosibirsk, , Russia

Site Status

Amarin Investigational Site

Petrozavodsk, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saint Petersburg, , Russia

Site Status

Amarin Investigational Site

Saratov, , Russia

Site Status

Amarin Investigational Site

Saratov, , Russia

Site Status

Amarin Investigational Site

Sestroretsk, Saint-Petersburg, , Russia

Site Status

Amarin Investigational Site

Tomsk, , Russia

Site Status

Amarin Investigational Site

Tomsk, , Russia

Site Status

Amarin Investigational Site

Volgograd, , Russia

Site Status

Amarin Investigational Site

Voronezh, , Russia

Site Status

Amarin Investigational Site

Voronezh, , Russia

Site Status

Amarin Investigational Site

Yaroslavl, , Russia

Site Status

Amarin Investigational Site

Yaroslavl, , Russia

Site Status

Amarin Investigational Site

Yekaterinburg, , Russia

Site Status

Amarin Investigational Site

Yekaterinburg, , Russia

Site Status

Amarin Investigational Site

Bloemfontein, Freestate, South Africa

Site Status

Amarin Investigational Site

Benoni, Gauteng, South Africa

Site Status

Amarin Investigational Site

Pretoria, Gauteng, South Africa

Site Status

Amarin Investigational Site

Soweto, Gauteng, South Africa

Site Status

Amarin Investigational Site

Witbank, Gauteng, South Africa

Site Status

Amarin Investigational Site

Durban, KwaZulu-Natal, South Africa

Site Status

Amarin Investigational Site

Newlands, KwaZulu-Natal, South Africa

Site Status

Amarin Investigational Site

Bellville, Western Cape, South Africa

Site Status

Amarin Investigational Site

Cape Town, Western Cape, South Africa

Site Status

Amarin Investigational Site

Durbanville, Western Cape, South Africa

Site Status

Amarin Investigational Site

Goodwood, Western Cape, South Africa

Site Status

Amarin Investigational Site

Kraaifontein, Western Cape, South Africa

Site Status

Amarin Investigational Site

Paarl, Western Cape, South Africa

Site Status

Amarin Investigational Site

Panorama, Western Cape, South Africa

Site Status

Amarin Investigational Site

Parow, Western Cape, South Africa

Site Status

Amarin Investigational Site

Pinelands, Western Cape, South Africa

Site Status

Amarin Investigational Site

Somerset West, Western Cape, South Africa

Site Status

Amarin Investigational Site

Worcester, Western Cape, South Africa

Site Status

Amarin Investigational Site

Lutsk, Volyn Oblast, Ukraine

Site Status

Amarin Investigational Site

Cherkasy, , Ukraine

Site Status

Amarin Investigational Site

Chernivtsi, , Ukraine

Site Status

Amarin Investigational Site

Dnipropetrovsk, , Ukraine

Site Status

Amarin Investigational Site

Dnipropetrovsk, , Ukraine

Site Status

Amarin Investigational Site

Dnipropetrovsk, , Ukraine

Site Status

Amarin Investigational Site

Donetsk, , Ukraine

Site Status

Amarin Investigational Site

Donetsk, , Ukraine

Site Status

Amarin Investigational Site

Ivano-Frankivsk, , Ukraine

Site Status

Amarin Investigational Site

Ivano-Frankivsk, , Ukraine

Site Status

Amarin Investigational Site

Kharkiv, , Ukraine

Site Status

Amarin Investigational Site

Kharkiv, , Ukraine

Site Status

Amarin Investigational Site

Kharkiv, , Ukraine

Site Status

Amarin Investigational Site

Kharkiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Kyiv, , Ukraine

Site Status

Amarin Investigational Site

Luhansk, , Ukraine

Site Status

Amarin Investigational Site

Lutsk, , Ukraine

Site Status

Amarin Investigational Site

Lviv, , Ukraine

Site Status

Amarin Investigational Site

Odesa, , Ukraine

Site Status

Amarin Investigational Site

Odesa, , Ukraine

Site Status

Amarin Investigational Site

Odesa, , Ukraine

Site Status

Amarin Investigational Site

Poltava, , Ukraine

Site Status

Amarin Investigational Site

Ternopil, , Ukraine

Site Status

Amarin Investigational Site

Uzhhorod, , Ukraine

Site Status

Amarin Investigational Site

Uzhhorod, , Ukraine

Site Status

Amarin Investigational Site

Vinnytsia, , Ukraine

Site Status

Amarin Investigational Site

Vinnytsia, , Ukraine

Site Status

Amarin Investigational Site

Zaporizhzhia, , Ukraine

Site Status

Amarin Investigational Site

Zaporizhzhia, , Ukraine

Site Status

Amarin Investigational Site

Zaporizhzhia, , Ukraine

Site Status

Amarin Investigational Site

Zaporizhzhia, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada India Netherlands New Zealand Poland Romania Russia South Africa Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM; REDUCE-IT Investigators. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar;40(3):138-148. doi: 10.1002/clc.22692. Epub 2017 Mar 15.

Reference Type BACKGROUND
PMID: 28294373 (View on PubMed)

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.

Reference Type RESULT
PMID: 30415628 (View on PubMed)

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.

Reference Type RESULT
PMID: 30898607 (View on PubMed)

Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM; REDUCE-IT Investigators. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 Feb 4;141(5):367-375. doi: 10.1161/CIRCULATIONAHA.119.044440. Epub 2019 Nov 11.

Reference Type RESULT
PMID: 31707829 (View on PubMed)

Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Mehta C, Mukherjee R, Ballantyne CM, Chung MK; REDUCE-IT Investigators. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e61-e63. doi: 10.1093/ehjcvp/pvaa118. No abstract available.

Reference Type RESULT
PMID: 33010162 (View on PubMed)

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation. 2021 Jan 5;143(1):33-44. doi: 10.1161/CIRCULATIONAHA.120.050276. Epub 2020 Nov 5.

Reference Type RESULT
PMID: 33148016 (View on PubMed)

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. J Am Coll Cardiol. 2019 Aug 27;74(8):1159-1161. doi: 10.1016/j.jacc.2019.06.043. No abstract available.

Reference Type RESULT
PMID: 31439224 (View on PubMed)

Gaba P, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Ballantyne CM, Pinto DS, Budoff MJ, Gibson CM. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. J Am Coll Cardiol. 2021 Oct 12;78(15):1525-1537. doi: 10.1016/j.jacc.2021.08.009.

Reference Type RESULT
PMID: 34620410 (View on PubMed)

Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Budoff M, Preston Mason R, Tardif JC, Boden WE, Ballantyne CM. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021 Nov 30;144(22):1750-1759. doi: 10.1161/CIRCULATIONAHA.121.055560. Epub 2021 Oct 28.

Reference Type RESULT
PMID: 34706555 (View on PubMed)

Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28.

Reference Type RESULT
PMID: 34710343 (View on PubMed)

Singh N, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Mason RP, Ballantyne CM; REDUCE-IT Investigators. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022 Jan 18;79(2):220-222. doi: 10.1016/j.jacc.2021.11.005. No abstract available.

Reference Type RESULT
PMID: 35027114 (View on PubMed)

Gurevitz C, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Lira Pineda A, Doyle RT Jr, Giugliano G, Mason RP, Tardif JC, Martens FMAC, Ballantyne CM, Budoff MJ, Gibson CM. Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT. Eur J Prev Cardiol. 2025 Sep 22:zwaf602. doi: 10.1093/eurjpc/zwaf602. Online ahead of print.

Reference Type DERIVED
PMID: 40982548 (View on PubMed)

Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, Dunbar RL, Ketchum SB, Tardif JC, Martens FMAC, Ballantyne CM, Szarek M, Mason RP; REDUCE-IT Investigators. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 4;14(5):e038656. doi: 10.1161/JAHA.124.038656. Epub 2025 Feb 19.

Reference Type DERIVED
PMID: 39968782 (View on PubMed)

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc. 2024 Jan 2;13(1):e032413. doi: 10.1161/JAHA.123.032413. Epub 2023 Dec 29.

Reference Type DERIVED
PMID: 38156550 (View on PubMed)

Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Pineda AL, Ketchum SB, Doyle RT Jr, Tardif JC, Ballantyne CM. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn. Eur Heart J Open. 2023 Nov 12;3(6):oead114. doi: 10.1093/ehjopen/oead114. eCollection 2023 Nov.

Reference Type DERIVED
PMID: 38035037 (View on PubMed)

Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Kowey PR, Reiffel JA, Tardif JC, Ballantyne CM, Chung MK; REDUCE-IT Investigators. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. J Am Heart Assoc. 2023 Mar 7;12(5):e026756. doi: 10.1161/JAHA.121.026756. Epub 2023 Feb 21.

Reference Type DERIVED
PMID: 36802845 (View on PubMed)

Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Bhatt DL. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 Aug 2;146(5):372-379. doi: 10.1161/CIRCULATIONAHA.122.059410. Epub 2022 Jun 28.

Reference Type DERIVED
PMID: 35762321 (View on PubMed)

Gaba P, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Giugliano RP, Martens FMAC, Gibson CM, Ballantyne CM; REDUCE-IT Investigators. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. J Am Coll Cardiol. 2022 May 3;79(17):1660-1671. doi: 10.1016/j.jacc.2022.02.035.

Reference Type DERIVED
PMID: 35483753 (View on PubMed)

Selvaraj S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Juliano RA, Jiao L, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022 Apr 5;11(7):e024999. doi: 10.1161/JAHA.121.024999. Epub 2022 Apr 4.

Reference Type DERIVED
PMID: 35377160 (View on PubMed)

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. J Am Heart Assoc. 2022 Mar 15;11(6):e022937. doi: 10.1161/JAHA.121.022937. Epub 2022 Mar 9.

Reference Type DERIVED
PMID: 35261279 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMR-01-01-0019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.